Skip to main content

Lidocaine with Epinephrine Injection Shortage

Last Updated: July 2, 2024
Status: Current

Products Affected - Description
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 1%, 20 mL vial, 100 count, NDC 00409-3178-01
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 1%, 30 mL vial, 100 count, NDC 00409-3178-02
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 1%, 50 mL vial, 100 count, NDC 00409-3178-03
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 2%, 20 mL vial, 100 count, NDC 00409-3182-01
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 2%, 30 mL vial, 100 count, NDC 00409-3182-02
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 2%, 50 mL vial, 100 count, NDC 00409-3182-03
    • Lidocaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 50 mL vial, 100 count, NDC 00409-3177-01
    • Lidocaine (with epinephrine 1:200,000) injection, Pfizer, 1.5%, 30 mL vial, 25 count, NDC 00409-3181-01
    • Lidocaine (with epinephrine 1:200,000) injection, Pfizer, 2%, 20 mL vial, 25 count, NDC 00409-3183-01
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 50 mL vial, 25 count, NDC 63323-0483-57
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 30 mL vial, sterile-pack 5 count, NDC 63323-0487-31
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 30 mL vial, 25 count, NDC 63323-0487-37
Reason for the Shortage
    • Fresenius Kabi has Xylocaine with epinephrine presentations available.
    • Pfizer has lidocaine with epinephrine presentations on shortage due to manufacturing delays and increased demand.
Available Products
    • Lidocaine (with epinephrine 1:200,000) injection, Pfizer, 1.5%, 5 mL glass ampule, 10 count, NDC 00409-1209-01
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.5%, 50 mL vial, 25 count, NDC 63323-0481-57
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 10 mL vial, 25 count, NDC 63323-0482-17
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 20 mL vial, 25 count, NDC 63323-0482-27
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 50 mL vial, 25 count, NDC 63323-0482-57
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 20 mL vial, 25 count, NDC 63323-0483-27
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 10 mL vial, 25 count, NDC 63323-0487-17
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1.5%, 10 mL vial, 25 count, NDC 63323-0488-17
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1.5%, 30 mL vial, 25 count, NDC 63323-0488-37
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 10 mL vial, 25 count, NDC 63323-0489-17
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 20 mL vial, 25 count, NDC 63323-0489-27

Estimated Resupply Dates

    • Pfizer has 0.5% lidocaine (1:200,000) 50 mL vials on back order and the company estimates a release date of April 2025. The 1% lidocaine (1:100,000) 20 mL, 30 mL, and 50 mL vials are on back order and the company estimates a release date of August 2024 for the 20 mL vials, November 2024 for the 30 mL vials, and February 2025 for the 50 mL vials. The 1.5% lidocaine (1:200,000) 30 mL vials are on back order and the company estimates a release date of March 2025. The 2% lidocaine (1:200,000) 20 mL vials are on back order and the company estimates a release date of February 2025. The 2% lidocaine (1:100,000) 20 mL, 30 mL, and 50 mL vials are on back order and the company estimates a release date of July 2025.

Updated

Updated July 2, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created November 16, 2011 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.